$4.36
0.00%
Nasdaq, Tue, Dec 30 2025
ISIN
US00773U1088
Symbol
ADVM

Adverum Biotechnologies Inc Stock price

$4.36
+0.16 3.81% 1M
+2.21 102.79% 6M
-0.31 6.64% YTD
-0.33 7.04% 1Y
-1.44 24.76% 3Y
-113.64 96.31% 5Y
-90.14 95.39% 10Y
-275.54 98.44% 20Y
Nasdaq, Closing price Tue, Dec 30 2025
+0.00 0.00%
ISIN
US00773U1088
Symbol
ADVM
Industry

Key metrics

Basic
Market capitalization
$96.3m
Enterprise Value
$70.2m
Net debt
positive
Cash
$26.1m
Shares outstanding
22.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 7.5
EV/Sales
- | 5.4
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
39.3%
Return on Equity
-185.2%
ROCE
-327.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $12.9m
EBITDA
$-88.2m | $-205.0m
EBIT
$-90.6m | $-191.5m
Net Income
$-88.6m | $-146.4m
Free Cash Flow
$-138.5m
Growth (TTM | estimate)
Revenue
-100.0% | 1,192.0%
EBITDA
24.3% | -51.3%
EBIT
24.7% | -37.6%
Net Income
20.4% | -11.8%
Free Cash Flow
-60.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,586.8%
EBIT
-
Net
- | -1,133.3%
Free Cash Flow
-
More
EPS
$-3.8
FCF per Share
$-6.3
Short interest
4.2%
Employees
155
Rev per Employee
$10.0k
Show more

Is Adverum Biotechnologies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,087 stocks worldwide.

Adverum Biotechnologies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Adverum Biotechnologies Inc forecast:

8x Buy
67%
4x Hold
33%

Analyst Opinions

12 Analysts have issued a Adverum Biotechnologies Inc forecast:

Buy
67%
Hold
33%

Financial data from Adverum Biotechnologies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
48% 48%
-
- Research and Development Expense 63 63
8% 8%
-
-88 -88
24% 24%
-
- Depreciation and Amortization 2.49 2.49
35% 35%
-
EBIT (Operating Income) EBIT -91 -91
25% 25%
-
Net Profit -89 -89
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Adverum Biotechnologies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adverum Biotechnologies Inc Stock News

Neutral
PRNewsWire
22 days ago
INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)  and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares ("Shares") of Adverum's common stock in exchange for (i) $3.56 pe...
Neutral
GlobeNewsWire
about one month ago
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by Eli Lilly and Company (“Lilly”).
Neutral
Business Wire
2 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum shareholders. Under the terms of the proposed transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferrable contingent value right (CVR) entitling the holder to ...
More Adverum Biotechnologies Inc News

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Head office United States
CEO Laurent Fischer
Employees 155
Founded 2006
Website adverum.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today